nodes	percent_of_prediction	percent_of_DWPC	metapath
Aclidinium—BCHE—Irinotecan—lung cancer	0.222	0.551	CbGbCtD
Aclidinium—BCHE—Cisplatin—lung cancer	0.181	0.449	CbGbCtD
Aclidinium—Infestation—Crizotinib—lung cancer	0.00636	0.015	CcSEcCtD
Aclidinium—Infestation NOS—Crizotinib—lung cancer	0.00636	0.015	CcSEcCtD
Aclidinium—Infestation—Pemetrexed—lung cancer	0.00581	0.0137	CcSEcCtD
Aclidinium—Infestation NOS—Pemetrexed—lung cancer	0.00581	0.0137	CcSEcCtD
Aclidinium—Infestation—Gefitinib—lung cancer	0.00577	0.0136	CcSEcCtD
Aclidinium—Infestation NOS—Gefitinib—lung cancer	0.00577	0.0136	CcSEcCtD
Aclidinium—Urinary tract disorder—Crizotinib—lung cancer	0.00564	0.0133	CcSEcCtD
Aclidinium—Urethral disorder—Crizotinib—lung cancer	0.00559	0.0132	CcSEcCtD
Aclidinium—Eye disorder—Crizotinib—lung cancer	0.00533	0.0125	CcSEcCtD
Aclidinium—Urinary tract disorder—Pemetrexed—lung cancer	0.00515	0.0121	CcSEcCtD
Aclidinium—Mediastinal disorder—Crizotinib—lung cancer	0.00514	0.0121	CcSEcCtD
Aclidinium—Urinary tract disorder—Gefitinib—lung cancer	0.00512	0.012	CcSEcCtD
Aclidinium—Urethral disorder—Pemetrexed—lung cancer	0.00511	0.012	CcSEcCtD
Aclidinium—Urethral disorder—Gefitinib—lung cancer	0.00508	0.0119	CcSEcCtD
Aclidinium—Eye disorder—Pemetrexed—lung cancer	0.00487	0.0115	CcSEcCtD
Aclidinium—Eye disorder—Gefitinib—lung cancer	0.00484	0.0114	CcSEcCtD
Aclidinium—Vision blurred—Crizotinib—lung cancer	0.00468	0.011	CcSEcCtD
Aclidinium—Mediastinal disorder—Gefitinib—lung cancer	0.00467	0.011	CcSEcCtD
Aclidinium—Dysphonia—Paclitaxel—lung cancer	0.00436	0.0103	CcSEcCtD
Aclidinium—Infection—Crizotinib—lung cancer	0.00403	0.00947	CcSEcCtD
Aclidinium—Nervous system disorder—Crizotinib—lung cancer	0.00398	0.00935	CcSEcCtD
Aclidinium—Cardiac failure—Vinorelbine—lung cancer	0.00397	0.00933	CcSEcCtD
Aclidinium—Cough—Gefitinib—lung cancer	0.00394	0.00926	CcSEcCtD
Aclidinium—Dry mouth—Gefitinib—lung cancer	0.00376	0.00883	CcSEcCtD
Aclidinium—Infection—Pemetrexed—lung cancer	0.00368	0.00866	CcSEcCtD
Aclidinium—Infection—Gefitinib—lung cancer	0.00366	0.0086	CcSEcCtD
Aclidinium—Nervous system disorder—Pemetrexed—lung cancer	0.00363	0.00855	CcSEcCtD
Aclidinium—Nervous system disorder—Gefitinib—lung cancer	0.00361	0.00849	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Crizotinib—lung cancer	0.0035	0.00823	CcSEcCtD
Aclidinium—Infestation NOS—Topotecan—lung cancer	0.00349	0.0082	CcSEcCtD
Aclidinium—Infestation—Topotecan—lung cancer	0.00349	0.0082	CcSEcCtD
Aclidinium—Infestation—Erlotinib—lung cancer	0.00345	0.00812	CcSEcCtD
Aclidinium—Infestation NOS—Erlotinib—lung cancer	0.00345	0.00812	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Pemetrexed—lung cancer	0.0032	0.00752	CcSEcCtD
Aclidinium—Osteoarthritis—Irinotecan—lung cancer	0.00319	0.00751	CcSEcCtD
Aclidinium—Cardiac failure—Gemcitabine—lung cancer	0.00319	0.0075	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Gefitinib—lung cancer	0.00318	0.00748	CcSEcCtD
Aclidinium—Rhinitis—Topotecan—lung cancer	0.00314	0.00738	CcSEcCtD
Aclidinium—Urinary tract disorder—Erlotinib—lung cancer	0.00306	0.0072	CcSEcCtD
Aclidinium—Urethral disorder—Erlotinib—lung cancer	0.00304	0.00714	CcSEcCtD
Aclidinium—Infestation—Vinorelbine—lung cancer	0.00298	0.00702	CcSEcCtD
Aclidinium—Infestation NOS—Vinorelbine—lung cancer	0.00298	0.00702	CcSEcCtD
Aclidinium—Infection—Teniposide—lung cancer	0.00298	0.00701	CcSEcCtD
Aclidinium—Tachycardia—Teniposide—lung cancer	0.00293	0.00689	CcSEcCtD
Aclidinium—Eye disorder—Erlotinib—lung cancer	0.00289	0.00681	CcSEcCtD
Aclidinium—Mediastinal disorder—Topotecan—lung cancer	0.00282	0.00664	CcSEcCtD
Aclidinium—Mediastinal disorder—Erlotinib—lung cancer	0.00279	0.00657	CcSEcCtD
Aclidinium—Diarrhoea—Crizotinib—lung cancer	0.00277	0.00652	CcSEcCtD
Aclidinium—Cardiac failure—Etoposide—lung cancer	0.00272	0.0064	CcSEcCtD
Aclidinium—Cardiac failure—Paclitaxel—lung cancer	0.00267	0.00628	CcSEcCtD
Aclidinium—Nasopharyngitis—Cisplatin—lung cancer	0.00259	0.0061	CcSEcCtD
Aclidinium—Vomiting—Crizotinib—lung cancer	0.00258	0.00606	CcSEcCtD
Aclidinium—Diarrhoea—Pemetrexed—lung cancer	0.00253	0.00596	CcSEcCtD
Aclidinium—Diarrhoea—Gefitinib—lung cancer	0.00252	0.00592	CcSEcCtD
Aclidinium—Mediastinal disorder—Vinorelbine—lung cancer	0.00241	0.00568	CcSEcCtD
Aclidinium—Cough—Topotecan—lung cancer	0.00238	0.00559	CcSEcCtD
Aclidinium—Vomiting—Pemetrexed—lung cancer	0.00236	0.00554	CcSEcCtD
Aclidinium—Cough—Erlotinib—lung cancer	0.00235	0.00553	CcSEcCtD
Aclidinium—Vomiting—Gefitinib—lung cancer	0.00234	0.00551	CcSEcCtD
Aclidinium—Nasopharyngitis—Paclitaxel—lung cancer	0.00233	0.00548	CcSEcCtD
Aclidinium—Dysphonia—Doxorubicin—lung cancer	0.00231	0.00543	CcSEcCtD
Aclidinium—Cardiac failure—Docetaxel—lung cancer	0.00226	0.00532	CcSEcCtD
Aclidinium—Rhinitis—Irinotecan—lung cancer	0.00221	0.00521	CcSEcCtD
Aclidinium—Infection—Topotecan—lung cancer	0.00221	0.0052	CcSEcCtD
Aclidinium—Infection—Erlotinib—lung cancer	0.00219	0.00514	CcSEcCtD
Aclidinium—Nervous system disorder—Topotecan—lung cancer	0.00218	0.00513	CcSEcCtD
Aclidinium—Nervous system disorder—Erlotinib—lung cancer	0.00216	0.00508	CcSEcCtD
Aclidinium—Rhinitis—Gemcitabine—lung cancer	0.00216	0.00507	CcSEcCtD
Aclidinium—Urinary tract disorder—Gemcitabine—lung cancer	0.00212	0.005	CcSEcCtD
Aclidinium—Urethral disorder—Gemcitabine—lung cancer	0.00211	0.00496	CcSEcCtD
Aclidinium—Diarrhoea—Teniposide—lung cancer	0.00205	0.00483	CcSEcCtD
Aclidinium—Infestation—Etoposide—lung cancer	0.00205	0.00481	CcSEcCtD
Aclidinium—Infestation NOS—Etoposide—lung cancer	0.00205	0.00481	CcSEcCtD
Aclidinium—Cough—Vinorelbine—lung cancer	0.00203	0.00479	CcSEcCtD
Aclidinium—Infestation NOS—Paclitaxel—lung cancer	0.00201	0.00472	CcSEcCtD
Aclidinium—Infestation—Paclitaxel—lung cancer	0.00201	0.00472	CcSEcCtD
Aclidinium—Mediastinal disorder—Irinotecan—lung cancer	0.00199	0.00468	CcSEcCtD
Aclidinium—Urinary tract disorder—Cisplatin—lung cancer	0.00198	0.00466	CcSEcCtD
Aclidinium—Nasopharyngitis—Docetaxel—lung cancer	0.00197	0.00464	CcSEcCtD
Aclidinium—Urethral disorder—Cisplatin—lung cancer	0.00197	0.00462	CcSEcCtD
Aclidinium—Mediastinal disorder—Gemcitabine—lung cancer	0.00194	0.00456	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Topotecan—lung cancer	0.00192	0.00452	CcSEcCtD
Aclidinium—Vomiting—Teniposide—lung cancer	0.00191	0.00449	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Erlotinib—lung cancer	0.0019	0.00447	CcSEcCtD
Aclidinium—Infection—Vinorelbine—lung cancer	0.00189	0.00445	CcSEcCtD
Aclidinium—Sinusitis—Paclitaxel—lung cancer	0.00188	0.00443	CcSEcCtD
Aclidinium—Headache—Teniposide—lung cancer	0.00188	0.00442	CcSEcCtD
Aclidinium—Eye disorder—Cisplatin—lung cancer	0.00187	0.00441	CcSEcCtD
Aclidinium—Nervous system disorder—Vinorelbine—lung cancer	0.00187	0.00439	CcSEcCtD
Aclidinium—Tachycardia—Vinorelbine—lung cancer	0.00186	0.00437	CcSEcCtD
Aclidinium—Diabetes mellitus—Methotrexate—lung cancer	0.00183	0.0043	CcSEcCtD
Aclidinium—Urinary tract disorder—Etoposide—lung cancer	0.00181	0.00427	CcSEcCtD
Aclidinium—Mediastinal disorder—Cisplatin—lung cancer	0.00181	0.00425	CcSEcCtD
Aclidinium—Rhinitis—Paclitaxel—lung cancer	0.00181	0.00425	CcSEcCtD
Aclidinium—Urethral disorder—Etoposide—lung cancer	0.0018	0.00424	CcSEcCtD
Aclidinium—Urinary tract disorder—Paclitaxel—lung cancer	0.00178	0.00418	CcSEcCtD
Aclidinium—Urethral disorder—Paclitaxel—lung cancer	0.00177	0.00415	CcSEcCtD
Aclidinium—Eye disorder—Etoposide—lung cancer	0.00172	0.00404	CcSEcCtD
Aclidinium—Infestation—Docetaxel—lung cancer	0.0017	0.004	CcSEcCtD
Aclidinium—Infestation NOS—Docetaxel—lung cancer	0.0017	0.004	CcSEcCtD
Aclidinium—Eye disorder—Paclitaxel—lung cancer	0.00168	0.00396	CcSEcCtD
Aclidinium—Cough—Irinotecan—lung cancer	0.00168	0.00395	CcSEcCtD
Aclidinium—Mediastinal disorder—Etoposide—lung cancer	0.00166	0.00389	CcSEcCtD
Aclidinium—Vision blurred—Cisplatin—lung cancer	0.00165	0.00387	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Vinorelbine—lung cancer	0.00164	0.00386	CcSEcCtD
Aclidinium—Cough—Gemcitabine—lung cancer	0.00163	0.00384	CcSEcCtD
Aclidinium—Mediastinal disorder—Paclitaxel—lung cancer	0.00162	0.00382	CcSEcCtD
Aclidinium—Osteoarthritis—Methotrexate—lung cancer	0.00159	0.00374	CcSEcCtD
Aclidinium—Diabetes mellitus—Doxorubicin—lung cancer	0.00158	0.00373	CcSEcCtD
Aclidinium—Diarrhoea—Vinblastine—lung cancer	0.00157	0.00368	CcSEcCtD
Aclidinium—Infection—Irinotecan—lung cancer	0.00156	0.00367	CcSEcCtD
Aclidinium—Nervous system disorder—Irinotecan—lung cancer	0.00154	0.00362	CcSEcCtD
Aclidinium—Rhinitis—Docetaxel—lung cancer	0.00153	0.0036	CcSEcCtD
Aclidinium—Diarrhoea—Topotecan—lung cancer	0.00152	0.00358	CcSEcCtD
Aclidinium—Infection—Gemcitabine—lung cancer	0.00152	0.00357	CcSEcCtD
Aclidinium—Urinary tract disorder—Docetaxel—lung cancer	0.00151	0.00355	CcSEcCtD
Aclidinium—Diarrhoea—Erlotinib—lung cancer	0.00151	0.00354	CcSEcCtD
Aclidinium—Nervous system disorder—Gemcitabine—lung cancer	0.0015	0.00353	CcSEcCtD
Aclidinium—Urethral disorder—Docetaxel—lung cancer	0.0015	0.00352	CcSEcCtD
Aclidinium—Vision blurred—Paclitaxel—lung cancer	0.00148	0.00348	CcSEcCtD
Aclidinium—Vomiting—Vinblastine—lung cancer	0.00146	0.00342	CcSEcCtD
Aclidinium—Headache—Vinblastine—lung cancer	0.00143	0.00337	CcSEcCtD
Aclidinium—Eye disorder—Docetaxel—lung cancer	0.00143	0.00336	CcSEcCtD
Aclidinium—Infection—Cisplatin—lung cancer	0.00142	0.00333	CcSEcCtD
Aclidinium—Vomiting—Topotecan—lung cancer	0.00141	0.00333	CcSEcCtD
Aclidinium—Cardiac failure—Doxorubicin—lung cancer	0.00141	0.00332	CcSEcCtD
Aclidinium—Vomiting—Erlotinib—lung cancer	0.0014	0.00329	CcSEcCtD
Aclidinium—Nervous system disorder—Cisplatin—lung cancer	0.0014	0.00329	CcSEcCtD
Aclidinium—Cough—Etoposide—lung cancer	0.0014	0.00328	CcSEcCtD
Aclidinium—Headache—Topotecan—lung cancer	0.00139	0.00328	CcSEcCtD
Aclidinium—Tachycardia—Cisplatin—lung cancer	0.00139	0.00327	CcSEcCtD
Aclidinium—Headache—Erlotinib—lung cancer	0.00138	0.00324	CcSEcCtD
Aclidinium—Osteoarthritis—Doxorubicin—lung cancer	0.00138	0.00324	CcSEcCtD
Aclidinium—Mediastinal disorder—Docetaxel—lung cancer	0.00138	0.00324	CcSEcCtD
Aclidinium—Cough—Paclitaxel—lung cancer	0.00137	0.00322	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Irinotecan—lung cancer	0.00135	0.00319	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Gemcitabine—lung cancer	0.00132	0.0031	CcSEcCtD
Aclidinium—Dry mouth—Paclitaxel—lung cancer	0.00131	0.00307	CcSEcCtD
Aclidinium—Diarrhoea—Vinorelbine—lung cancer	0.0013	0.00306	CcSEcCtD
Aclidinium—Infection—Etoposide—lung cancer	0.0013	0.00305	CcSEcCtD
Aclidinium—Tachycardia—Etoposide—lung cancer	0.00127	0.003	CcSEcCtD
Aclidinium—Infection—Paclitaxel—lung cancer	0.00127	0.00299	CcSEcCtD
Aclidinium—Nervous system disorder—Paclitaxel—lung cancer	0.00126	0.00295	CcSEcCtD
Aclidinium—Tachycardia—Paclitaxel—lung cancer	0.00125	0.00294	CcSEcCtD
Aclidinium—Nasopharyngitis—Doxorubicin—lung cancer	0.00123	0.0029	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Cisplatin—lung cancer	0.00123	0.00289	CcSEcCtD
Aclidinium—Infestation—Methotrexate—lung cancer	0.00123	0.00288	CcSEcCtD
Aclidinium—Infestation NOS—Methotrexate—lung cancer	0.00123	0.00288	CcSEcCtD
Aclidinium—Vomiting—Vinorelbine—lung cancer	0.00121	0.00285	CcSEcCtD
Aclidinium—Headache—Vinorelbine—lung cancer	0.00119	0.0028	CcSEcCtD
Aclidinium—Cough—Docetaxel—lung cancer	0.00116	0.00273	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Etoposide—lung cancer	0.00113	0.00265	CcSEcCtD
Aclidinium—Dry mouth—Docetaxel—lung cancer	0.00111	0.0026	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Paclitaxel—lung cancer	0.0011	0.0026	CcSEcCtD
Aclidinium—Urinary tract disorder—Methotrexate—lung cancer	0.00109	0.00256	CcSEcCtD
Aclidinium—Urethral disorder—Methotrexate—lung cancer	0.00108	0.00254	CcSEcCtD
Aclidinium—Infection—Docetaxel—lung cancer	0.00108	0.00253	CcSEcCtD
Aclidinium—Diarrhoea—Irinotecan—lung cancer	0.00107	0.00253	CcSEcCtD
Aclidinium—Nervous system disorder—Docetaxel—lung cancer	0.00106	0.0025	CcSEcCtD
Aclidinium—Infestation NOS—Doxorubicin—lung cancer	0.00106	0.0025	CcSEcCtD
Aclidinium—Infestation—Doxorubicin—lung cancer	0.00106	0.0025	CcSEcCtD
Aclidinium—Tachycardia—Docetaxel—lung cancer	0.00106	0.00249	CcSEcCtD
Aclidinium—Diarrhoea—Gemcitabine—lung cancer	0.00105	0.00246	CcSEcCtD
Aclidinium—BCHE—diaphragm—lung cancer	0.00103	0.513	CbGeAlD
Aclidinium—Eye disorder—Methotrexate—lung cancer	0.00103	0.00242	CcSEcCtD
Aclidinium—Vomiting—Irinotecan—lung cancer	0.000998	0.00235	CcSEcCtD
Aclidinium—Sinusitis—Doxorubicin—lung cancer	0.000996	0.00234	CcSEcCtD
Aclidinium—Mediastinal disorder—Methotrexate—lung cancer	0.000992	0.00233	CcSEcCtD
Aclidinium—Headache—Irinotecan—lung cancer	0.000983	0.00231	CcSEcCtD
Aclidinium—Diarrhoea—Cisplatin—lung cancer	0.000975	0.00229	CcSEcCtD
Aclidinium—Vomiting—Gemcitabine—lung cancer	0.000972	0.00229	CcSEcCtD
Aclidinium—Headache—Gemcitabine—lung cancer	0.000958	0.00225	CcSEcCtD
Aclidinium—Rhinitis—Doxorubicin—lung cancer	0.000955	0.00225	CcSEcCtD
Aclidinium—Urinary tract disorder—Doxorubicin—lung cancer	0.000941	0.00221	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Docetaxel—lung cancer	0.000937	0.0022	CcSEcCtD
Aclidinium—Urethral disorder—Doxorubicin—lung cancer	0.000934	0.0022	CcSEcCtD
Aclidinium—Vomiting—Cisplatin—lung cancer	0.000906	0.00213	CcSEcCtD
Aclidinium—Vision blurred—Methotrexate—lung cancer	0.000903	0.00212	CcSEcCtD
Aclidinium—Diarrhoea—Etoposide—lung cancer	0.000893	0.0021	CcSEcCtD
Aclidinium—Eye disorder—Doxorubicin—lung cancer	0.000891	0.00209	CcSEcCtD
Aclidinium—Diarrhoea—Paclitaxel—lung cancer	0.000876	0.00206	CcSEcCtD
Aclidinium—Mediastinal disorder—Doxorubicin—lung cancer	0.000859	0.00202	CcSEcCtD
Aclidinium—Cough—Methotrexate—lung cancer	0.000836	0.00197	CcSEcCtD
Aclidinium—Vomiting—Etoposide—lung cancer	0.00083	0.00195	CcSEcCtD
Aclidinium—Headache—Etoposide—lung cancer	0.000818	0.00192	CcSEcCtD
Aclidinium—Vomiting—Paclitaxel—lung cancer	0.000814	0.00191	CcSEcCtD
Aclidinium—Headache—Paclitaxel—lung cancer	0.000802	0.00189	CcSEcCtD
Aclidinium—Vision blurred—Doxorubicin—lung cancer	0.000782	0.00184	CcSEcCtD
Aclidinium—Infection—Methotrexate—lung cancer	0.000777	0.00183	CcSEcCtD
Aclidinium—Nervous system disorder—Methotrexate—lung cancer	0.000767	0.0018	CcSEcCtD
Aclidinium—Diarrhoea—Docetaxel—lung cancer	0.000742	0.00175	CcSEcCtD
Aclidinium—Cough—Doxorubicin—lung cancer	0.000724	0.0017	CcSEcCtD
Aclidinium—Dry mouth—Doxorubicin—lung cancer	0.000691	0.00162	CcSEcCtD
Aclidinium—Vomiting—Docetaxel—lung cancer	0.00069	0.00162	CcSEcCtD
Aclidinium—Headache—Docetaxel—lung cancer	0.00068	0.0016	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Methotrexate—lung cancer	0.000675	0.00159	CcSEcCtD
Aclidinium—Infection—Doxorubicin—lung cancer	0.000673	0.00158	CcSEcCtD
Aclidinium—Nervous system disorder—Doxorubicin—lung cancer	0.000664	0.00156	CcSEcCtD
Aclidinium—Tachycardia—Doxorubicin—lung cancer	0.000661	0.00155	CcSEcCtD
Aclidinium—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000585	0.00137	CcSEcCtD
Aclidinium—Diarrhoea—Methotrexate—lung cancer	0.000535	0.00126	CcSEcCtD
Aclidinium—Vomiting—Methotrexate—lung cancer	0.000497	0.00117	CcSEcCtD
Aclidinium—Headache—Methotrexate—lung cancer	0.00049	0.00115	CcSEcCtD
Aclidinium—Diarrhoea—Doxorubicin—lung cancer	0.000463	0.00109	CcSEcCtD
Aclidinium—Vomiting—Doxorubicin—lung cancer	0.00043	0.00101	CcSEcCtD
Aclidinium—Headache—Doxorubicin—lung cancer	0.000424	0.000998	CcSEcCtD
Aclidinium—CHRM5—epithelium—lung cancer	0.000215	0.107	CbGeAlD
Aclidinium—CHRM1—trachea—lung cancer	0.000119	0.0593	CbGeAlD
Aclidinium—BCHE—respiratory system—lung cancer	0.000117	0.0586	CbGeAlD
Aclidinium—BCHE—bronchus—lung cancer	9.67e-05	0.0482	CbGeAlD
Aclidinium—BCHE—trachea—lung cancer	8.68e-05	0.0433	CbGeAlD
Aclidinium—CHRM1—lung—lung cancer	8.54e-05	0.0426	CbGeAlD
Aclidinium—BCHE—cardiac atrium—lung cancer	8.16e-05	0.0407	CbGeAlD
Aclidinium—BCHE—bone marrow—lung cancer	6.89e-05	0.0344	CbGeAlD
Aclidinium—BCHE—lung—lung cancer	6.24e-05	0.0311	CbGeAlD
Aclidinium—BCHE—lymph node—lung cancer	4.27e-05	0.0213	CbGeAlD
Aclidinium—CHRM5—Signaling Pathways—MAP2K1—lung cancer	3.42e-05	0.000202	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—PIK3CD—lung cancer	3.4e-05	0.0002	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—CXCL8—lung cancer	3.39e-05	0.0002	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—CXCL8—lung cancer	3.38e-05	0.000199	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—ERBB3—lung cancer	3.37e-05	0.000199	CbGpPWpGaD
Aclidinium—CHRM5—GPCR downstream signaling—PIK3CA—lung cancer	3.37e-05	0.000198	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—ERBB3—lung cancer	3.36e-05	0.000198	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—CXCL8—lung cancer	3.35e-05	0.000197	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—ERBB3—lung cancer	3.33e-05	0.000196	CbGpPWpGaD
Aclidinium—CHRM5—Signaling by GPCR—KRAS—lung cancer	3.33e-05	0.000196	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—PIK3CG—lung cancer	3.25e-05	0.000191	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—IL2—lung cancer	3.24e-05	0.000191	CbGpPWpGaD
Aclidinium—BCHE—Metabolism—PIK3CB—lung cancer	3.23e-05	0.00019	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—IL2—lung cancer	3.23e-05	0.00019	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—TERT—lung cancer	3.23e-05	0.00019	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—TERT—lung cancer	3.22e-05	0.00019	CbGpPWpGaD
Aclidinium—BCHE—Metabolism—PTGS2—lung cancer	3.21e-05	0.000189	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—IL2—lung cancer	3.2e-05	0.000189	CbGpPWpGaD
Aclidinium—CHRM4—Signaling by GPCR—PIK3CA—lung cancer	3.19e-05	0.000188	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—TERT—lung cancer	3.19e-05	0.000188	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—MDM2—lung cancer	3.18e-05	0.000187	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—RAF1—lung cancer	3.17e-05	0.000187	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—FGFR1—lung cancer	3.14e-05	0.000185	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—ERBB2—lung cancer	3.14e-05	0.000185	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—FGFR1—lung cancer	3.13e-05	0.000184	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—FGFR1—lung cancer	3.1e-05	0.000182	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—MTOR—lung cancer	3.09e-05	0.000182	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—PIK3CB—lung cancer	3.09e-05	0.000182	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—HIF1A—lung cancer	3.09e-05	0.000182	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—POMC—lung cancer	3.09e-05	0.000182	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—HIF1A—lung cancer	3.08e-05	0.000181	CbGpPWpGaD
Aclidinium—CHRM5—Signaling by GPCR—PIK3CA—lung cancer	3.06e-05	0.00018	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—HIF1A—lung cancer	3.05e-05	0.00018	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—MDM2—lung cancer	3.05e-05	0.000179	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—RAF1—lung cancer	3.04e-05	0.000179	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—CREBBP—lung cancer	3.01e-05	0.000177	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—ERBB2—lung cancer	3e-05	0.000177	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—APOA1—lung cancer	2.98e-05	0.000176	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—CXCL8—lung cancer	2.97e-05	0.000175	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—APOA1—lung cancer	2.97e-05	0.000175	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—PIK3CB—lung cancer	2.96e-05	0.000174	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—MTOR—lung cancer	2.96e-05	0.000174	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—KDR—lung cancer	2.96e-05	0.000174	CbGpPWpGaD
Aclidinium—CHRM4—Signaling by GPCR—HRAS—lung cancer	2.95e-05	0.000174	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—KDR—lung cancer	2.95e-05	0.000174	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—APOA1—lung cancer	2.94e-05	0.000173	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—KDR—lung cancer	2.92e-05	0.000172	CbGpPWpGaD
Aclidinium—CHRM4—GPCR downstream signaling—AKT1—lung cancer	2.87e-05	0.000169	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—PIK3CD—lung cancer	2.85e-05	0.000168	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—CXCL8—lung cancer	2.85e-05	0.000168	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—CASP3—lung cancer	2.85e-05	0.000168	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—IL2—lung cancer	2.84e-05	0.000167	CbGpPWpGaD
Aclidinium—CHRM5—Signaling by GPCR—HRAS—lung cancer	2.83e-05	0.000167	CbGpPWpGaD
Aclidinium—CHRM4—Signaling by GPCR—IL6—lung cancer	2.83e-05	0.000167	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—ALB—lung cancer	2.82e-05	0.000166	CbGpPWpGaD
Aclidinium—BCHE—Metabolism—PTEN—lung cancer	2.8e-05	0.000165	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—CCND1—lung cancer	2.77e-05	0.000163	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—JUN—lung cancer	2.76e-05	0.000163	CbGpPWpGaD
Aclidinium—CHRM5—GPCR downstream signaling—AKT1—lung cancer	2.75e-05	0.000162	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—CASP3—lung cancer	2.73e-05	0.00016	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—PIK3CG—lung cancer	2.72e-05	0.00016	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—APC—lung cancer	2.72e-05	0.00016	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—KIT—lung cancer	2.72e-05	0.00016	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—NRAS—lung cancer	2.72e-05	0.00016	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—IL2—lung cancer	2.72e-05	0.00016	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—KIT—lung cancer	2.71e-05	0.00016	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—PIK3CG—lung cancer	2.71e-05	0.00016	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—APC—lung cancer	2.71e-05	0.00016	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—NRAS—lung cancer	2.71e-05	0.00016	CbGpPWpGaD
Aclidinium—CHRM5—Signaling by GPCR—IL6—lung cancer	2.71e-05	0.000159	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—EGF—lung cancer	2.69e-05	0.000158	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—MMP9—lung cancer	2.69e-05	0.000158	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—PIK3CG—lung cancer	2.69e-05	0.000158	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—KIT—lung cancer	2.69e-05	0.000158	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—APC—lung cancer	2.69e-05	0.000158	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—NRAS—lung cancer	2.69e-05	0.000158	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—EGF—lung cancer	2.68e-05	0.000158	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—CDKN1A—lung cancer	2.68e-05	0.000158	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—PTEN—lung cancer	2.67e-05	0.000157	CbGpPWpGaD
Aclidinium—BCHE—Metabolism—EP300—lung cancer	2.67e-05	0.000157	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—EGF—lung cancer	2.66e-05	0.000156	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—CCND1—lung cancer	2.65e-05	0.000156	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—JUN—lung cancer	2.65e-05	0.000156	CbGpPWpGaD
Aclidinium—CHRM4—Signaling by GPCR—AKT1—lung cancer	2.61e-05	0.000154	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—MAPK3—lung cancer	2.61e-05	0.000154	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—MAPK3—lung cancer	2.6e-05	0.000153	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—POMC—lung cancer	2.59e-05	0.000153	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—POMC—lung cancer	2.58e-05	0.000152	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—MMP9—lung cancer	2.58e-05	0.000152	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—MAPK3—lung cancer	2.57e-05	0.000152	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—CDKN1A—lung cancer	2.57e-05	0.000151	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—PTEN—lung cancer	2.56e-05	0.000151	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—BRAF—lung cancer	2.56e-05	0.000151	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—POMC—lung cancer	2.56e-05	0.000151	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—BRAF—lung cancer	2.55e-05	0.00015	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—EP300—lung cancer	2.55e-05	0.00015	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—IL6R—lung cancer	2.53e-05	0.000149	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—BRAF—lung cancer	2.53e-05	0.000149	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CREBBP—lung cancer	2.52e-05	0.000149	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—IL6R—lung cancer	2.52e-05	0.000148	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CREBBP—lung cancer	2.52e-05	0.000148	CbGpPWpGaD
Aclidinium—CHRM5—Signaling by GPCR—AKT1—lung cancer	2.5e-05	0.000147	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—IL6R—lung cancer	2.5e-05	0.000147	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CREBBP—lung cancer	2.49e-05	0.000147	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—PIK3CB—lung cancer	2.49e-05	0.000146	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—EGFR—lung cancer	2.48e-05	0.000146	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—SRC—lung cancer	2.48e-05	0.000146	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—EGFR—lung cancer	2.47e-05	0.000146	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—PTGS2—lung cancer	2.46e-05	0.000145	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—EGFR—lung cancer	2.45e-05	0.000144	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—EP300—lung cancer	2.44e-05	0.000144	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—VEGFA—lung cancer	2.42e-05	0.000142	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—MAP2K1—lung cancer	2.41e-05	0.000142	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—MAP2K1—lung cancer	2.4e-05	0.000141	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—PIK3CD—lung cancer	2.39e-05	0.000141	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—STAT3—lung cancer	2.39e-05	0.000141	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—PIK3CD—lung cancer	2.39e-05	0.000141	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—NRAS—lung cancer	2.39e-05	0.00014	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—MAP2K1—lung cancer	2.38e-05	0.00014	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—SRC—lung cancer	2.37e-05	0.00014	CbGpPWpGaD
Aclidinium—CHRM1—GPCR downstream signaling—PIK3CA—lung cancer	2.37e-05	0.00014	CbGpPWpGaD
Aclidinium—CHRM3—GPCR downstream signaling—PIK3CA—lung cancer	2.36e-05	0.000139	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—PIK3CD—lung cancer	2.36e-05	0.000139	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—KRAS—lung cancer	2.34e-05	0.000138	CbGpPWpGaD
Aclidinium—CHRM2—GPCR downstream signaling—PIK3CA—lung cancer	2.34e-05	0.000138	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—KRAS—lung cancer	2.34e-05	0.000138	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—KRAS—lung cancer	2.31e-05	0.000136	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—VEGFA—lung cancer	2.31e-05	0.000136	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—STAT3—lung cancer	2.29e-05	0.000135	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—MAPK3—lung cancer	2.28e-05	0.000135	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—NRAS—lung cancer	2.28e-05	0.000135	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—MYC—lung cancer	2.22e-05	0.000131	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—MAPK3—lung cancer	2.19e-05	0.000129	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—EGFR—lung cancer	2.17e-05	0.000128	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—PIK3CA—lung cancer	2.15e-05	0.000127	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—PTEN—lung cancer	2.15e-05	0.000127	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—PIK3CA—lung cancer	2.15e-05	0.000126	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—MDM2—lung cancer	2.14e-05	0.000126	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—MDM2—lung cancer	2.14e-05	0.000126	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—RAF1—lung cancer	2.14e-05	0.000126	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—RAF1—lung cancer	2.13e-05	0.000125	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—MYC—lung cancer	2.13e-05	0.000125	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—PIK3CA—lung cancer	2.13e-05	0.000125	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—MDM2—lung cancer	2.12e-05	0.000125	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—ERBB2—lung cancer	2.11e-05	0.000124	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—RAF1—lung cancer	2.11e-05	0.000124	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—ERBB2—lung cancer	2.11e-05	0.000124	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—ERBB2—lung cancer	2.09e-05	0.000123	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—PIK3CB—lung cancer	2.09e-05	0.000123	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—MTOR—lung cancer	2.09e-05	0.000123	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—EGFR—lung cancer	2.08e-05	0.000123	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—PIK3CB—lung cancer	2.08e-05	0.000122	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—MTOR—lung cancer	2.08e-05	0.000122	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—MTOR—lung cancer	2.06e-05	0.000121	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—PIK3CB—lung cancer	2.06e-05	0.000121	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—KRAS—lung cancer	2.05e-05	0.000121	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—EP300—lung cancer	2.05e-05	0.000121	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CXCL8—lung cancer	2.01e-05	0.000118	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CXCL8—lung cancer	2e-05	0.000118	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—HRAS—lung cancer	1.99e-05	0.000117	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—HRAS—lung cancer	1.99e-05	0.000117	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CXCL8—lung cancer	1.98e-05	0.000117	CbGpPWpGaD
Aclidinium—BCHE—Metabolism—PIK3CA—lung cancer	1.97e-05	0.000116	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—HRAS—lung cancer	1.97e-05	0.000116	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—KRAS—lung cancer	1.97e-05	0.000116	CbGpPWpGaD
Aclidinium—CHRM1—GPCR downstream signaling—AKT1—lung cancer	1.94e-05	0.000114	CbGpPWpGaD
Aclidinium—CHRM3—GPCR downstream signaling—AKT1—lung cancer	1.93e-05	0.000114	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CASP3—lung cancer	1.92e-05	0.000113	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—IL2—lung cancer	1.92e-05	0.000113	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CASP3—lung cancer	1.91e-05	0.000113	CbGpPWpGaD
Aclidinium—CHRM2—GPCR downstream signaling—AKT1—lung cancer	1.91e-05	0.000113	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—IL2—lung cancer	1.91e-05	0.000112	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—IL6—lung cancer	1.91e-05	0.000112	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—IL6—lung cancer	1.9e-05	0.000112	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CASP3—lung cancer	1.89e-05	0.000112	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—IL2—lung cancer	1.89e-05	0.000111	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—PIK3CA—lung cancer	1.89e-05	0.000111	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—IL6—lung cancer	1.88e-05	0.000111	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CCND1—lung cancer	1.87e-05	0.00011	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—JUN—lung cancer	1.86e-05	0.00011	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CCND1—lung cancer	1.86e-05	0.00011	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—JUN—lung cancer	1.86e-05	0.000109	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CCND1—lung cancer	1.84e-05	0.000109	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—JUN—lung cancer	1.84e-05	0.000108	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—TP53—lung cancer	1.83e-05	0.000107	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—MMP9—lung cancer	1.81e-05	0.000107	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—MMP9—lung cancer	1.81e-05	0.000106	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—CDKN1A—lung cancer	1.81e-05	0.000106	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—PIK3CA—lung cancer	1.81e-05	0.000106	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—PTEN—lung cancer	1.8e-05	0.000106	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—CDKN1A—lung cancer	1.8e-05	0.000106	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—PTEN—lung cancer	1.8e-05	0.000106	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—MMP9—lung cancer	1.79e-05	0.000105	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—CDKN1A—lung cancer	1.78e-05	0.000105	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—PTEN—lung cancer	1.78e-05	0.000105	CbGpPWpGaD
Aclidinium—CHRM1—Signaling by GPCR—AKT1—lung cancer	1.76e-05	0.000104	CbGpPWpGaD
Aclidinium—CHRM3—Signaling by GPCR—AKT1—lung cancer	1.75e-05	0.000103	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—TP53—lung cancer	1.75e-05	0.000103	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—HRAS—lung cancer	1.75e-05	0.000103	CbGpPWpGaD
Aclidinium—CHRM2—Signaling by GPCR—AKT1—lung cancer	1.74e-05	0.000102	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—EP300—lung cancer	1.72e-05	0.000101	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—EP300—lung cancer	1.71e-05	0.000101	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—EP300—lung cancer	1.7e-05	9.99e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—SRC—lung cancer	1.67e-05	9.85e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—HRAS—lung cancer	1.67e-05	9.84e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—IL6—lung cancer	1.67e-05	9.84e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—SRC—lung cancer	1.67e-05	9.81e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—SRC—lung cancer	1.65e-05	9.72e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—VEGFA—lung cancer	1.63e-05	9.59e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—VEGFA—lung cancer	1.62e-05	9.56e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—STAT3—lung cancer	1.61e-05	9.49e-05	CbGpPWpGaD
Aclidinium—BCHE—Metabolism—AKT1—lung cancer	1.61e-05	9.49e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—NRAS—lung cancer	1.61e-05	9.47e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—VEGFA—lung cancer	1.61e-05	9.47e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—STAT3—lung cancer	1.61e-05	9.46e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—NRAS—lung cancer	1.6e-05	9.44e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—IL6—lung cancer	1.6e-05	9.42e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—STAT3—lung cancer	1.59e-05	9.37e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—NRAS—lung cancer	1.59e-05	9.35e-05	CbGpPWpGaD
Aclidinium—CHRM4—Signaling Pathways—AKT1—lung cancer	1.54e-05	9.07e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—MAPK3—lung cancer	1.54e-05	9.07e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—MAPK3—lung cancer	1.54e-05	9.04e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—MAPK3—lung cancer	1.52e-05	8.95e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—PIK3CA—lung cancer	1.52e-05	8.93e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—MYC—lung cancer	1.5e-05	8.82e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—MYC—lung cancer	1.49e-05	8.79e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—MYC—lung cancer	1.48e-05	8.71e-05	CbGpPWpGaD
Aclidinium—CHRM5—Signaling Pathways—AKT1—lung cancer	1.48e-05	8.69e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—EGFR—lung cancer	1.47e-05	8.63e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—EGFR—lung cancer	1.46e-05	8.6e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—EGFR—lung cancer	1.45e-05	8.52e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—KRAS—lung cancer	1.38e-05	8.15e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—KRAS—lung cancer	1.38e-05	8.13e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—KRAS—lung cancer	1.37e-05	8.05e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—PIK3CA—lung cancer	1.27e-05	7.49e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—PIK3CA—lung cancer	1.27e-05	7.47e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—PIK3CA—lung cancer	1.26e-05	7.39e-05	CbGpPWpGaD
Aclidinium—CHRM3—Metabolism—AKT1—lung cancer	1.24e-05	7.29e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—TP53—lung cancer	1.23e-05	7.25e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—TP53—lung cancer	1.23e-05	7.22e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—TP53—lung cancer	1.21e-05	7.15e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—HRAS—lung cancer	1.18e-05	6.93e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—HRAS—lung cancer	1.17e-05	6.91e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—HRAS—lung cancer	1.16e-05	6.84e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—IL6—lung cancer	1.13e-05	6.63e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—IL6—lung cancer	1.12e-05	6.61e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—IL6—lung cancer	1.11e-05	6.55e-05	CbGpPWpGaD
Aclidinium—CHRM1—Signaling Pathways—AKT1—lung cancer	1.04e-05	6.12e-05	CbGpPWpGaD
Aclidinium—CHRM3—Signaling Pathways—AKT1—lung cancer	1.04e-05	6.1e-05	CbGpPWpGaD
Aclidinium—CHRM2—Signaling Pathways—AKT1—lung cancer	1.03e-05	6.04e-05	CbGpPWpGaD
